Radiosensitisation of Squamous Cell Carcinoma of the Penis in Men Who Are Positive for Human Papillomavirus Infection

Human papillomavirus (HPV) is associated with up to 4.5% of all cancer cases and is a significant healthcare burden, with 600 000 cases per annum. HPV vaccination has been introduced globally to mitigate this public health risk. Prophylactic vaccines against high-risk (HPV-16 and HPV-18) and low-risk (HPV-6 and HPV-11) HPV subtypes have revolutionised the field. More recently, there has been a focus on the role of HPV in disease prognosis and treatment. In this issue of European Urology Oncology, Bandini et al [ [1] ] report a retrospective analysis of the role of HPV as a prognostic factor for response to radiotherapy in the treatment of penile squamous cell carcinoma (PSCC) following lymph node dissection.

Nicholas Raison, Imperial Urology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK
Suks Minhas, Department of Urology, Imperial College Healthcare NHS Trust, Charing Cross Hospital, London, UK.

References:

Bandini M., Zhu Y., Ye D.W. et al. Association between human papillomavirus infection and outcome of perioperative nodal radiotherapy for penile carcinoma. Eur Urol Oncol. 2021; 4: 802-810

Source: Nicholas Raison, Suks Minhas, Radiosensitisation of Squamous Cell Carcinoma of the Penis in Men Who Are Positive for Human Papillomavirus Infection, European Urology Oncology, Volume 4, Issue 5, 2021, Pages 811-812, ISSN 2588-9311

Login